Breast, Omega 3 Free Fatty Acid, Ph 0

Prospective, single arm, short term study with correlative biomarker endpoints. Two hundred
(200) newly diagnosed breast cancer patients will be recruited to participate in a short term
(30 day) Phase 0 biomarker evaluation study prior to surgical resection. Patients will be
receive fish Oil (Omega-3 FFAs, 2700 mg by mouth twice daily).

Inclusion Criteria:

- At least 18 years of age

- ECOG ≤2

- Ability to understand the purposes and risks of the study and has signed a written
informed consent form approved by the investigator's IRB/Ethics Committee

- Consented for tissue collection on CTRC repository 07-32

Exclusion Criteria:

- Active systemic illness (infection including viral illnesses such as Hepatitis and
HIV)

- Chronic use of NSAIDs or omega-3 free fatty acid supplementation within the last 60
days (defined as greater than or equal to 7 consecutive days)

- Any NSAIDs or omega-3 free fatty acid supplementation within the last 14 days

- History of medical noncompliance

- Scheduled date of surgical resection that would limit the amount of time taking the
intervention to less than 21 days